|
|
Article: Journal of Diabetes and Its Complications Publishes Favorable Study Addressing Quigley Pharma's Diabetic Neuropathy Formulation QR-333.
- Article from:
- PR Newswire
- Article date:
- September 7, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Topical Compound May Safely Offer Relief for the Treatment of Symptomatic Diabetic Peripheral Neuropathy
DOYLESTOWN, Penn., Sept. 7 /PRNewswire-FirstCall/ -- Quigley Pharma, a wholly owned subsidiary of Quigley Corporation , announced today that a preliminary report of QR-333, a topical compound for the treatment of diabetic neuropathy, was recently featured in the Journal of Diabetes and Its Complications. Authored by Dr. C. LeFante and Dr. P. Valensi, the article appeared in the June 1, 2005 issue, and included findings that showed QR-333 reduced the severity of numbness, jolting pain, and irritation from baseline values.
According to estimates from ...